A New Generation of Serotype Chimeric Infectivity-Enhanced Conditionally Replicative Adenovirals: The Safety Profile of Ad5/3-Δ24 in Advance of a Phase I Clinical Trial in Ovarian Cancer Patients

Conditionally replicative adenoviral (CRAd) virotherapy represents a promising therapeutic approach for cancer. We have demonstrated that a serotype chimeric adenoviral 5/3 fiber-knob modification achieves enhanced ovarian cancer infectivity, conditional replication, and oncolytic activity. This stu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kim, Kenneth H., Ryan, Michael J., Estep, James E., Miniard, Brock M., Rudge, Thomas L., Peggins, James O., Broadt, Trevor L., Wang, Minghui, Preuss, Meredith A., Siegal, Gene P., Hemminki, Akseli, Harris, Raymond D., Aurigemma, Rosemarie, Curiel, David T., Alvarez, Ronald D.
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc. 2011
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3135257/
https://ncbi.nlm.nih.gov/pubmed/21171861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/hum.2010.180
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados